NEW HAVEN, Conn., March 8 /PRNewswire/ -- Ikonisys, Inc., a medical technology company focused on the development of products for prenatal and cancer diagnosis and screening and fertility, today announced the closing of a $10 million Series D private equity financing. The round was led by Trevi Health Ventures, with a strong syndicate of existing and other new investors, including St. Simeon Lda, New Science Ventures, WHI Group and Lakeview Capital Management. With this financing, Ikonisys expects to rapidly advance its prenatal diagnostics program to FDA submission and further develop its oncology program.
“We are excited to close this round of financing with the participation of investors of such high quality who add significant value to our enterprise. This financing will facilitate the completion of the clinical development of the fetal cell detection test, a test that could significantly impact the health care of its intended users and help position Ikonisys in the center of an exciting segment of the diagnostic market,” said Petros Tsipouras, Chairman and Chief Executive Officer of Ikonisys.
“We are very impressed with the robotic microscopy platform Ikonisys has developed and the progress that the Company has made in its prenatal and cancer diagnostic product lines. Researchers and companies have for years been seeking a prenatal diagnostic system that is accurate and non-invasive and that can sustain high-volume throughput, and we are excited that Ikonisys appears to be succeeding in accomplishing these goals where many others have failed,” commented Andrew Fink, Managing Director of Trevi Health Ventures.
Ikonisys has developed the Ikoniscope(TM)/IkoniLAN(TM), a robotic microscopy system for fully automated and high-throughput rare cell detection and analysis. The fetal cell test will provide non-invasive prenatal diagnosis for chromosomal abnormalities by analyzing a small sample of maternal blood to detect circulating fetal cells. The Company is also developing several oncology products based on the utilization of its robotic microscopy system.
About Ikonisys
Ikonisys is a medical technology company that is developing products for prenatal and cancer diagnosis. Based on its proprietary technology, Ikonisys aims to expand a novel field of medical diagnostic analysis, namely cell-based diagnostics. Additional information about Ikonisys can be found at http://www.ikonisys.com.
Contact: Petros Tsipouras, MD Chairman and CEO Ikonisys, Inc. Phone Number: 203-776-0791 Email: tsipouras@ikonisys.com This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Source: Ikonisys, Inc.
